BRENUS PHARMA

Brenus Pharma is a clinical-stage biotech developing first-in-class in vivo immunotherapies through an off-the-shelf platform designed to unlock immune responses against solid tumors.

This proprietary technology mimics tumor protein expression and makes it visible. It unveils the widest panel of cancer-associated antigens capable of educating the immune system to fight back against evolving tumor cells.

With €30M raised since inception and CTA approval, Brenus has initiated its first-in-human Phase I/II trial (NCT06934538) in patients with advanced or metastatic colorectal cancer, the second leading cause of cancer-related death worldwide.

The trial is currently underway, with the first patients recruited in Europe and expansion planned in the U.S.

The Brenus platform is standardized and GMP-ready, applying precision medicine principles at scale. It aims to address patients’ medical needs, control time and costs of supply, and reach broader patient populations where personalized therapies remain limited.